Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers13215479
Title: Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway
Authors: Arora, Loukik
Mohan, Chakrabhavi Dhananjaya
Yang, Min Hee
Rangappa, Shobith
Deivasigamani, Amudha
Kumar, Alan Prem 
Kunnumakkara, Ajaikumar B.
Garg, Manoj
Chinnathambi, Arunachalam
Alharbi, Sulaiman Ali
Alahmadi, Tahani Awad
Rangappa, Kanchugarakoppal S.
Hui, Kam Man 
Sethi, Gautam 
Ahn, Kwang Seok
Keywords: Orthotopic
SHP2
STAT3 signaling inhibitor
Tris DBA
Xenograft
Issue Date: 31-Oct-2021
Publisher: MDPI
Citation: Arora, Loukik, Mohan, Chakrabhavi Dhananjaya, Yang, Min Hee, Rangappa, Shobith, Deivasigamani, Amudha, Kumar, Alan Prem, Kunnumakkara, Ajaikumar B., Garg, Manoj, Chinnathambi, Arunachalam, Alharbi, Sulaiman Ali, Alahmadi, Tahani Awad, Rangappa, Kanchugarakoppal S., Hui, Kam Man, Sethi, Gautam, Ahn, Kwang Seok (2021-10-31). Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway. Cancers 13 (21) : 5479. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13215479
Rights: Attribution 4.0 International
Abstract: STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Cancers
URI: https://scholarbank.nus.edu.sg/handle/10635/232792
ISSN: 2072-6694
DOI: 10.3390/cancers13215479
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers13215479.pdf26.41 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons